Dr. Gearóid Tuohy

Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.

A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.

ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10  using a novel therapy for “Sepofarsen” (QR-110)

A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10  using a novel therapy for “Sepofarsen” (QR-110)